182 related articles for article (PubMed ID: 24389444)
41. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
Rosell R; Karachaliou N; Wolf J; Ou SH
Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
[No Abstract] [Full Text] [Related]
42. The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.
Toyooka S; Date H; Uchida A; Kiura K; Takata M
Clin Cancer Res; 2007 Jun; 13(11):3431; author reply 3431-2. PubMed ID: 17545553
[No Abstract] [Full Text] [Related]
43. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
Browning ET; Weickhardt AJ; Camidge DR
J Thorac Oncol; 2013 Mar; 8(3):e21. PubMed ID: 23407562
[No Abstract] [Full Text] [Related]
44. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.
Cortese JF; Gowda AL; Wali A; Eliason JF; Pass HI; Everson RB
Int J Cancer; 2006 Jan; 118(2):521-2. PubMed ID: 16052537
[No Abstract] [Full Text] [Related]
45. Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy.
Gu FF; Zhang Y; Liu YY; Hong XH; Liang JY; Tong F; Yang JS; Liu L
J Hematol Oncol; 2016 Aug; 9(1):66. PubMed ID: 27496196
[TBL] [Abstract][Full Text] [Related]
46. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
Yano S; Wang W; Li Q; Matsumoto K; Sakurama H; Nakamura T; Ogino H; Kakiuchi S; Hanibuchi M; Nishioka Y; Uehara H; Mitsudomi T; Yatabe Y; Nakamura T; Sone S
Cancer Res; 2008 Nov; 68(22):9479-87. PubMed ID: 19010923
[TBL] [Abstract][Full Text] [Related]
47. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
48. Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma.
Zito Marino F; Morabito A; Gridelli C; Rocco G; Liguori G; De Rosa N; Botti G; Franco R
Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):e86-e88. PubMed ID: 26990744
[TBL] [Abstract][Full Text] [Related]
49. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
[TBL] [Abstract][Full Text] [Related]
50. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
[TBL] [Abstract][Full Text] [Related]
51. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
[TBL] [Abstract][Full Text] [Related]
52. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
[TBL] [Abstract][Full Text] [Related]
53. Does the addition of vascular endothelial growth factor inhibitors to epidermal growth factor receptor-tyrosine kinase inhibitor overcome T790M acquired resistance?
Hata A; Kaji R; Fujita S; Katakami N
J Thorac Oncol; 2011 Feb; 6(2):404. PubMed ID: 21252723
[No Abstract] [Full Text] [Related]
54. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T
Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008
[TBL] [Abstract][Full Text] [Related]
55. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
56. Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies.
Kobayashi Y; Sakao Y; Ito S; Park J; Kuroda H; Sakakura N; Usami N; Mitsudomi T; Yatabe Y
J Thorac Oncol; 2013 Aug; 8(8):e75-8. PubMed ID: 23857406
[No Abstract] [Full Text] [Related]
57. Crizotinib: an anaplastic lymphoma kinase inhibitor.
Gadgeel SM; Bepler G
Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
[TBL] [Abstract][Full Text] [Related]
58. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
59. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
Zhang Y; Yin J; Peng F
Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
[No Abstract] [Full Text] [Related]
60. Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
Azzoli CG
Ann Surg Oncol; 2015 Oct; 22(11):3459-65. PubMed ID: 26215190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]